ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CAB ULA

Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 3, since Jun 10, 20262 company-led studies, 2 open or runningNext primary completion: Mar 8, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 3since Jun 10, 2026Jan 15, 2025Mar 8, 2027phase 1 · NCT06786520

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2025First study: phase 1 study in HIV InfectionsFirst studyNCT06786520 · 69 enrolled · United States
  2. Jun 10, 2026Phase 3 study in HIVPhase 3 reachedNCT07650916 · 564 planned · United States, Argentina, Australia and more

Ahead

  1. Mar 8, 2027Primary completion: phase 1 study in HIV InfectionsNCT06786520
  2. Aug 13, 2029Primary completion: phase 3 study in HIVNCT07650916

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07650916HIV · United States, Argentina, Australia and more3RecruitingAug 13, 2029564
NCT06786520HIV Infections · United States1Active, not recruitingMar 8, 202769

How it is read

Names in the registry

  • “CAB ULA”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.